ライフサイエンスコーパス: intracranial hypertension

1 ence of contraindications (i.e., preexisting intracranial hypertension).

2 <100 beats/min plus mannitol (250 mg/kg) for intracranial hypertension.

3 blood pressure >100 mm Hg plus mannitol for intracranial hypertension.

4 signs/symptoms experienced by patients with intracranial hypertension.

5 c brain injury or other pathology leading to intracranial hypertension.

6 headache, anemia, fatigue, hypertension, and intracranial hypertension.

7 pinal fluid of some patients with idiopathic intracranial hypertension.

8 lay a role in the pathogenesis of idiopathic intracranial hypertension.

9 ate coma as outlined above failed to control intracranial hypertension.

10 25-30 torr (3.33-4.00 kPa) was used to treat intracranial hypertension.

11 atients develop cerebral injury secondary to intracranial hypertension.

12 fer from a high frequency rate of idiopathic intracranial hypertension.

13 after transplantation, primarily because of intracranial hypertension.

14 rease intracranial pressure in patients with intracranial hypertension.

15 cranial hypotension is more rare than benign intracranial hypertension.

16 id replacement are probable causes of benign intracranial hypertension.

17 centers had a protocol for the treatment of intracranial hypertension.

18 had low sensitivity (11%-42%) for detecting intracranial hypertension.

19 of ocular imaging in 21 patients with known intracranial hypertension.

20 tified, excluding those with other causes of intracranial hypertension.

21 hemorrhagic meningoencephalitis with severe intracranial hypertension.

22 nist, on intracranial pressure in idiopathic intracranial hypertension.

23 for identifying critically ill patients with intracranial hypertension.

24 cranial pressure monitoring and treatment of intracranial hypertension.

25 surgical vs medical treatment for traumatic intracranial hypertension.

26 medical or surgical interventions to manage intracranial hypertension.

27 Ten patients were diagnosed with idiopathic intracranial hypertension.

28 arious forms of hydrocephalus and ideopathic intracranial hypertension.

29 rs or longer if patients remained at risk of intracranial hypertension.

30 NVs in this cohort have been associated with intracranial hypertension.

31 racranial pressure in 91.7% of patients with intracranial hypertension.

32 ing optic disc oedema that resemble signs of intracranial hypertension.

33 d/or midazolam for the treatment of episodic intracranial hypertension.

34 generally present with signs and symptoms of intracranial hypertension.

35 re, deep vein thrombosis, and uncontrollable intracranial hypertension.

36 ension burden when administered for episodic intracranial hypertension.

37 ry correlated with Deltaarea under the curve-intracranial hypertension.

38 aumatic brain injury, hypothermia can reduce intracranial hypertension.

39 ve drugs, and medical/surgical therapies for intracranial hypertension.

40 luded tolerability, systemic hypotension and intracranial hypertension.

41 sion, mass effect, infection, hemorrhage, or intracranial hypertension.

42 dure for the management of swollen brain and intracranial hypertension.

43 therapy in refractory status epilepticus and intracranial hypertension.

44 and scored intensity of therapies targeting intracranial hypertension.

45 nificantly in the population not affected by intracranial hypertension.

46 nial findings similar to those in idiopathic intracranial hypertension.

47 th severe subarachnoid hemorrhage not having intracranial hypertension.

48 regarding the pathophysiology of idiopathic intracranial hypertension.

49 presence and severity of papilledema, due to intracranial hypertension.

50 with low to intermediate risk of developing intracranial hypertension.

51 optic neuropathy (NAION), conditions without intracranial hypertension.

52 establish the first-line medical therapy for intracranial hypertension.

53 uropathy (AION), and 25 with papilledema and intracranial hypertension.

54 all aggregate mean Deltaarea under the curve-intracranial hypertension = +17 mm Hg x min, 95% CI, 0-3

55 21-day mortality was higher in patients with intracranial hypertension (43% vs 23%, p = 0.05).

56 -MS disease controls, PHOMS were observed in intracranial hypertension (62%), optic disc drusen (47%)

57 Pseudotumor cerebri (also called idiopathic intracranial hypertension), a known complication of seve

58 oring enables the detection and treatment of intracranial hypertension, a potentially lethal insult a

59 Idiopathic intracranial hypertension affects 3.44 per 10 000 women

60 nts during the surgical management of severe intracranial hypertension after traumatic brain injury (

61 ltiple time points, including development of intracranial hypertension and 6-month mortality.

62 Nine patients with uncontrolled intracranial hypertension and ALF who fulfilled the crit

63 fect might be attributed to the reduction of intracranial hypertension and alterations in the cerebra

64 Non-invasive detection of intracranial hypertension and assessment of cerebral per

65 st possible systemic associations, including intracranial hypertension and autoimmune markers.

66 Intracranial hypertension and cerebral edema are known c

67 d with a risk of brain injury resulting from intracranial hypertension and cerebral hypoperfusion.

68 icantly higher in patients with uncontrolled intracranial hypertension and cerebral ischemia post-SAH

69 All the patients had intracranial hypertension and cerebral oedema.

70 ns for understanding glaucoma and idiopathic intracranial hypertension and could help explain visual

71 ses of pulsatile tinnitus include idiopathic intracranial hypertension and dural arteriovenous fistul

72 tanding of the pathophysiology of idiopathic intracranial hypertension and glaucoma.

73 to proceed to a phase 3 trial in idiopathic intracranial hypertension and highlight the potential to

74 han in the group of patients with idiopathic intracranial hypertension and in each respective state a

75 mon-and often the presenting-symptom of both intracranial hypertension and intracranial hypotension s

76 Hyperammonemia has been associated with intracranial hypertension and mortality in patients with

77 f jugular venous desaturation and refractory intracranial hypertension and on long-term neurologic ou

78 Hypothermia is also effective in mitigating intracranial hypertension and reducing brain edema.

79 s in diagnosis or misdiagnosis of idiopathic intracranial hypertension and spontaneous intracranial h

80 physiology and the mechanisms of idiopathic intracranial hypertension and spontaneous intracranial h

81 To improve the diagnosis of idiopathic intracranial hypertension and spontaneous intracranial h

82 If left untreated, idiopathic intracranial hypertension and spontaneous intracranial h

83 s provide accurate and timely predictions of intracranial hypertension and tissue hypoxia crises in p

84 and unconsciousness used to treat refractory intracranial hypertension and to manage treatment-resist

85 ts with clinical or radiographic evidence of intracranial hypertension and/or cerebral swelling were

86 nnot be identified (also known as idiopathic intracranial hypertension), and secondary pseudotumor ce

87 monitoring modalities used, the treatment of intracranial hypertension, and general care of severely

88 ated with the development of cerebral edema, intracranial hypertension, and secondary neuronal injury

89 to use corticosteroids for the treatment of intracranial hypertension as a result of head trauma.

90 patients with severe acute brain trauma and intracranial hypertension associated with compromised ce

91 ata suggest that in FHF patients who develop intracranial hypertension before OLT, dissection of the

92 oxically, we observed an overall increase in intracranial hypertension burden following drug administ

93 f fentanyl and midazolam fails to reduce the intracranial hypertension burden when administered for e

94 Decompressive craniectomy prevents intracranial hypertension but does not clearly improve p

95 cranial pressure can lead to the reversal of intracranial hypertension, but in most patients cerebral

96 eritoneal shunting in children is idiopathic intracranial hypertension, but the technique is also use

97 Craniectomy may prevent intracranial hypertension, but whether it is associated

98 pressure while supine, and during simulated intracranial hypertension by 15 degrees head-down tilt.

99 sed intracranial pressure and had documented intracranial hypertension, cerebral oedema, or both.

100 8) months in the hydrocephalus and suspected intracranial hypertension cohort (60% female), and 59.7

101 saline, have been used for the management of intracranial hypertension crises and as a measure to pre

102 Intracranial hypertension developed in 62 (33.7%) patien

103 In severe cases of cerebral edema, intracranial hypertension develops and leads to brain de

104 al pressure monitored patients received more intracranial hypertension-directed therapies (mannitol,

105 or patients with previously known idiopathic intracranial hypertension, ED stay decreased from 24 hou

106 ebrospinal fluid of patients with idiopathic intracranial hypertension, elevated intracranial pressur

107 for central pontine myelinolysis and rebound intracranial hypertension exists with uncontrolled admin

108 plots was calculated to represent cumulative intracranial hypertension exposure: area under the curve

109 re often used as second-tier strategies when intracranial hypertension following severe traumatic bra

110 craniectomy for the treatment of refractory intracranial hypertension following traumatic brain inju

111 (mean age = 25 yr) who developed refractory intracranial hypertension following traumatic brain inju

112 ta was performed for patients with traumatic intracranial hypertension (>25 mm Hg) from 52 centers in

113 surgically treated posttraumatic refractory intracranial hypertension had a sustained reduction in m

114 our of the eight patients with pretransplant intracranial hypertension had six episodes of ICP increa

115 Decompressive craniectomy in refractory intracranial hypertension has been associated with poor

116 The primary goal of identifying and treating intracranial hypertension has given way to a focus on se

117 diatric traumatic brain injury before severe intracranial hypertension has the potential to be neurop

118 ugh the demographics of pediatric idiopathic intracranial hypertension have been well described, the

119 in developing countries, and can also cause intracranial hypertension, hydrocephalus and death.

120 lopment, seizure probability and timing, and intracranial hypertension/hydrocephalus, respectively.

121 Assessment of combined impact of intracranial hypertension (ICH) and obstructive sleep ap

122 However, development of intracranial hypertension (ICH) may be affected by facto

123 ociated with hepatic encephalopathy (HE) and intracranial hypertension (ICH).

124 The ability to detect intracranial hypertension (ICP >/= 20 mm Hg) was highest

125 Magnetic resonance imaging (MRI) signs of intracranial hypertension (IH) are traditionally associa

126 of induced hypernatremia on the incidence of intracranial hypertension (IH) in patients with ALF.

127 elevated ICP, a dangerous condition known as intracranial hypertension (IH).

128 alues of ONSD to be used in the diagnosis of intracranial hypertension (IHT).

129 c management and prevention and treatment of intracranial hypertension (IHTN).

130 the population-based incidence of idiopathic intracranial hypertension (IIH) and to determine if it m

131 umor cerebri (PTC-T) and those of idiopathic intracranial hypertension (IIH) are absent in the litera

132 iteria currently used to diagnose idiopathic intracranial hypertension (IIH) are based on expert opin

133 ociated with papilledema owing to idiopathic intracranial hypertension (IIH) at presentation.

134 Idiopathic intracranial hypertension (IIH) can present with severe

135 Idiopathic intracranial hypertension (IIH) causes headaches, vision

136 The understanding of idiopathic intracranial hypertension (IIH) has evolved over the pas

137 Idiopathic intracranial hypertension (IIH) is a condition in which

138 Idiopathic Intracranial Hypertension (IIH) is a neurological disord

139 Idiopathic intracranial hypertension (IIH) is a potentially blindin

140 Idiopathic intracranial hypertension (IIH) is a rare but important

141 enesis and treatment paradigm for idiopathic intracranial hypertension (IIH) is controversial.

142 thalmological findings similar to idiopathic intracranial hypertension (IIH) patients.

143 ohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the dise

144 retinal changes in patients with idiopathic intracranial hypertension (IIH) using fundus photography

145 olamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficie

146 are traditionally associated with idiopathic intracranial hypertension (IIH), but these signs are als

147 quired optic disc swelling due to idiopathic intracranial hypertension (IIH), non-arteritic anterior

148 g 250mmH(2)O is key in diagnosing idiopathic intracranial hypertension (IIH), per revised Friedman's

149 erns of visual field (VF) loss in idiopathic intracranial hypertension (IIH), referred to as archetyp

150 in the diagnosis and treatment of idiopathic intracranial hypertension (IIH).

151 ual loss is the main morbidity of idiopathic intracranial hypertension (IIH).

152 ed MR venography in patients with idiopathic intracranial hypertension (IIH).

153 woman with a history of presumed idiopathic intracranial hypertension ("IIH") presented with new hea

154 with the development of vasogenic edema and intracranial hypertension in a number of neurological di

155 o standard therapy, as firstline therapy for intracranial hypertension in certain intracranial pathol

156 may warrant consideration as a treatment for intracranial hypertension in children with severe TBI.

157 A similar proportion died due to refractory intracranial hypertension in each group (abusive head tr

158 hypothermia could be tested for treatment of intracranial hypertension in fulminant hepatic failure.

159 terature and literature on the management of intracranial hypertension in non-acute liver failure pat

160 ults, hypothermia reduces cerebral edema and intracranial hypertension in patients with acute liver f

161 Intracranial hypertension in patients with acute liver f

162 ulted in worsening of cerebral hyperemia and intracranial hypertension in patients with ALF and sever

163 Increased CBF contributes to intracranial hypertension in patients with ALF.

164 Hypothermia reduces intracranial hypertension in patients with traumatic bra

165 racterize the occurrence and significance of intracranial hypertension in severe intraventricular hem

166 t patients during surgical decompression for intracranial hypertension in the acute phase after traum

167 The management of benign intracranial hypertension includes, symptomatic headache

168 ffect, and time after injury as a covariate, intracranial hypertension increased after administration

169 The mean Deltaarea under the curve-intracranial hypertension increased significantly after

170 of patients with papilloedema and idiopathic intracranial hypertension, inflammatory optic neuropathi

171 tailed information, 44 (51%) had evidence of intracranial hypertension (intracranial pressure > 25 mm

172 enrolled adult women with active idiopathic intracranial hypertension (intracranial pressure >25 cmC

173 Idiopathic intracranial hypertension is a disease of unknown aetiol

174 Idiopathic intracranial hypertension is a disorder characterised by

175 Benign intracranial hypertension is a rare syndrome of increase

176 tions of giant cell arteritis and idiopathic intracranial hypertension is classified herein according

177 Idiopathic intracranial hypertension is common in obese women and c

178 monitored patients with acute liver failure, intracranial hypertension is commonly observed.

179 The incidence of idiopathic intracranial hypertension is expected to increase as rat

180 The effectiveness of treatments that address intracranial hypertension is generally assessed by measu

181 severe cerebrovascular disease and impending intracranial hypertension is safe and might reduce the f

182 Benign intracranial hypertension is though to be caused by cere

183 Prediction of intracranial hypertension management, pulmonary infectio

184 ral blood patch, a rebound and self-limiting intracranial hypertension may sometimes develop.

185 h acute liver failure (ALF) and uncontrolled intracranial hypertension, moderate hypothermia (32 degr

186 of patients with hydrocephalus and suspected intracranial hypertension (n = 5), and the negative cont

187 These episodes of intracranial hypertension occurred during failing liver

188 Benign intracranial hypertension often has no abnormal imaging

189 Pediatric intracranial hypertension patients may be followed with

190 Of the 10 idiopathic intracranial hypertension patients, 3 had a previous his

191 with multiple sclerosis (MS), (2) idiopathic intracranial hypertension (pseudotumor cerebri), (3) non

192 55 mmol/L may be considered in patients with intracranial hypertension refractory to mannitol.

193 tcomes in patients with refractory traumatic intracranial hypertension remains unclear.

194 ients with hemorrhagic shock, as therapy for intracranial hypertension resistant to standard therapy,

195 s with traumatic brain injury and refractory intracranial hypertension resulted in lower mortality an

196 similar numbers of patients with idiopathic intracranial hypertension seen in the same services were

197 arious forms of hydrocephalus and idiopathic intracranial hypertension.SIGNIFICANCE STATEMENT Effecti

198 ues are used to look for secondary causes of intracranial hypertension such as cerebral venous sinus

199 ght; this differs from reports in idiopathic intracranial hypertension, suggesting differences in the

200 admitted to our Emergency Department with an intracranial hypertension syndrome.

201 asis of hypothermia in patients with ALF and intracranial hypertension that is unresponsive to standa

202 Intracranial hypertension treatment guided by monitoring

203 Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) report

204 o month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

205 The Idiopathic Intracranial Hypertension Treatment Trial represents the

206 Intracranial hypertension was suspected on physical exam

207 ressure above 20 mm Hg (area under the curve-intracranial hypertension) was calculated in 15-minute e

208 nistration epochs (Deltaarea under the curve-intracranial hypertension), was calculated for all occur

209 5-year randomized clinical trial (Idiopathic Intracranial Hypertension Weight Trial) enrolled women w